Stoke Therapeutics, Inc. (STOK)
25.04
-0.66
(-2.57%)
USD |
NASDAQ |
Oct 23, 16:00
25.03
-0.01
(-0.04%)
After-Hours: 20:00
Stoke Therapeutics Enterprise Value : 1.272B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 1.272B |
| October 22, 2026 | 1.314B |
| October 21, 2026 | 1.312B |
| October 20, 2026 | 1.370B |
| October 19, 2026 | 1.259B |
| October 16, 2026 | 1.218B |
| October 15, 2026 | 1.246B |
| October 14, 2026 | 1.161B |
| October 13, 2026 | 1.114B |
| October 12, 2026 | 1.217B |
| October 09, 2026 | 1.254B |
| October 08, 2026 | 1.204B |
| October 07, 2026 | 1.226B |
| October 06, 2026 | 1.231B |
| October 05, 2026 | 1.290B |
| October 02, 2026 | 1.309B |
| October 01, 2026 | 1.333B |
| September 30, 2026 | 1.332B |
| September 29, 2026 | 1.325B |
| September 28, 2026 | 1.301B |
| September 25, 2026 | 1.257B |
| September 24, 2026 | 1.288B |
| September 23, 2026 | 1.339B |
| September 22, 2026 | 1.532B |
| September 21, 2026 | 1.460B |
| Date | Value |
|---|---|
| September 18, 2026 | 1.484B |
| September 17, 2026 | 1.515B |
| September 16, 2026 | 1.452B |
| September 15, 2026 | 1.466B |
| September 14, 2026 | 1.557B |
| September 11, 2026 | 1.521B |
| September 10, 2026 | 1.541B |
| September 09, 2026 | 1.577B |
| September 08, 2026 | 1.585B |
| September 04, 2026 | 1.570B |
| September 03, 2026 | 1.581B |
| September 02, 2026 | 1.613B |
| September 01, 2026 | 1.637B |
| August 31, 2026 | 1.657B |
| August 28, 2026 | 1.683B |
| August 27, 2026 | 1.744B |
| August 26, 2026 | 1.775B |
| August 25, 2026 | 1.798B |
| August 24, 2026 | 1.727B |
| August 21, 2026 | 1.725B |
| August 20, 2026 | 1.669B |
| August 19, 2026 | 1.771B |
| August 18, 2026 | 1.715B |
| August 17, 2026 | 1.715B |
| August 14, 2026 | 1.661B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 534.42M |
| Amgen, Inc. | 280.78B |
| Anika Therapeutics, Inc. | 273.50M |
| BioCryst Pharmaceuticals, Inc. | 2.436B |
| Imunon, Inc. | 6.743M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -61.62M |
| Revenue (Quarterly) | 9.325M |
| Total Expenses (Quarterly) | 70.94M |
| EPS Diluted (Quarterly) | -0.9334 |
| Gross Profit Margin (Quarterly) | 87.80% |
| Profit Margin (Quarterly) | -660.8% |
| Earnings Yield | -13.47% |
| Normalized Earnings Yield | -13.47 |